Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney , Sydney, NSW , Australia ; Sydney Medical School and Bosch Institute, The University of Sydney , Sydney, NSW , Australia.
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney , Sydney, NSW , Australia.
Front Oncol. 2014 Aug 15;4:220. doi: 10.3389/fonc.2014.00220. eCollection 2014.
The successful treatment of cancer is hampered by drug resistance and metastasis. While these two obstacles were once considered separately, recent evidence associates resistance with an enhanced metastatic capacity. However, the underlying mechanisms remain undefined. We previously described the intercellular transfer of drug resistance via submicron vesicles called microparticles (MPs). We now propose that MPs derived from drug-resistant cells are also involved in the intercellular transfer of components to enhance the migration and invasion capacity of cells. Thus, MPs may be a conduit between resistance and metastasis. We used microarray analysis to identify regulatory microRNAs (miRNAs), which contribute to the dissemination of metastatic traits. miR-503 was downregulated in recipient cells following co-culture with MPs isolated from drug-resistant cells. miR-503 was inversely associated with metastasis, as demonstrated using wound healing/scratch migration assays and Matrigel(®)-coated transwell invasion assays. Proline-rich tyrosine kinase 2 (PYK2) was upregulated in recipient cells and associated with increased migration and invasion, with these phenotypes being reversed using a pharmacological inhibitor of PYK2 phosphorylation, tyrphostin A9. However, the MP-mediated promotion of metastatic traits was not due to the presence of these effectors in the MP cargo but rather due to down stream effector molecules in these pathways. This is the first demonstration that the role of MPs in trait acquisition extends beyond the direct transfer of vesicle components and also includes transfer of intermediary regulators that induce down stream mediators following transfer to recipient cells. This implicates an expanding role of MPs in cancer pathogenesis.
癌症的成功治疗受到耐药性和转移的阻碍。虽然这两个障碍曾经被认为是分开的,但最近的证据将耐药性与增强的转移能力联系起来。然而,潜在的机制尚不清楚。我们之前描述了通过称为微泡(microparticles,MPs)的亚微米囊泡进行耐药性的细胞间转移。我们现在提出,来自耐药细胞的 MPs 也参与了增强细胞迁移和侵袭能力的细胞间成分转移。因此,MPs 可能是耐药性和转移之间的通道。我们使用微阵列分析来鉴定有助于转移特征传播的调节 microRNA(miRNA)。在用 MPs 与耐药细胞共培养后,miR-503 在受体细胞中下调。miR-503 与转移呈负相关,这一点通过划痕愈合/划痕迁移测定和 Matrigel(®)包被的 Transwell 侵袭测定得到证实。受体细胞中富含脯氨酸的酪氨酸激酶 2(PYK2)上调,并与迁移和侵袭增加相关,使用 PYK2 磷酸化的药理学抑制剂 tyrphostin A9 逆转了这些表型。然而,MP 介导的促进转移特征不是由于 MP 货物中存在这些效应物,而是由于这些途径中的下游效应分子。这是第一个证明 MPs 在获得特征中的作用不仅限于囊泡成分的直接转移,还包括转移到受体细胞后诱导下游介质的中间调节剂的转移。这暗示了 MPs 在癌症发病机制中的作用不断扩大。